Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER study)

Trial Profile

Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER study)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms MASTER
  • Sponsors Roche

Most Recent Events

  • 22 Jul 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 15 Feb 2011 New source identified and integrated (ClinicalTrials.gov record).
  • 09 Dec 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top